Q-omics provides the consensus-scored C7orf26 profile across patient tissues and cancer cell-line models. C7orf26 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, C7orf26 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, C7orf26 RNA expression shows 19,506 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KICH, KIRC, and ACC as cancer lineages where C7orf26 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C7orf26 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C7orf26 survival associations across molecular data types. C7orf26 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C7orf26 RNA expression–survival associations across cancer types. High C7orf26 expression shows unfavorable associations in KICH, HNSC, ACC, LIHC and LGG, but favorable associations in PAAD. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for C7orf26 RNA expression.
This table summarizes C7orf26 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for C7orf26. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C7orf26 shows lower tumor expression in THCA and higher tumor expression in KIRC, LIHC, COAD, HNSC and STAD. The KIRC box plot shows higher C7orf26 RNA expression in tumor versus normal tissue (log2 FC = +0.434, t-test p < 0.001).
This table shows molecular features associated with C7orf26 in patient tissues and cancer cell lines. In patient samples, C7orf26 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, C7orf26 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
